Neuropace Short Term Debt vs Total Liab Analysis

NPCE Stock

USD 7.98 0.19 2.33%

Neuropace financial indicator trend analysis is infinitely more than just investigating Neuropace recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neuropace is a good investment. Please check the relationship between Neuropace Short Term Debt and its Total Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.

Short Term Debt vs Total Liab

Short Term Debt vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neuropace Short Term Debt account and Total Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between Neuropace's Short Term Debt and Total Liab is 0.6. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Total Liab in the same time period over historical financial statements of Neuropace, assuming nothing else is changed. The correlation between historical values of Neuropace's Short Term Debt and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Neuropace are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Short Term Debt i.e., Neuropace's Short Term Debt and Total Liab go up and down completely randomly.

Correlation Coefficient

0.6

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Short Term Debt

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Neuropace's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neuropace current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.The current year's Enterprise Value is expected to grow to about 433.9 M, whereas Selling General Administrative is forecasted to decline to about 44.6 M.

	2021	2022	2023	2024 (projected)
Gross Profit	33.4M	32.5M	48.1M	37.6M
Total Revenue	45.2M	45.5M	65.4M	51.5M

Gross Profit Total Revenue

Neuropace fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		0.02	0.88	-0.93	0.96	-0.98	0.96	0.7	-0.93	-0.47	-0.85	0.85	0.69	0.7	0.6	0.57	0.99	0.7	0.68	0.98	-0.1	0.61	0.92	0.88	-0.84	0.95
Short Long Term Debt Total	0.02		0.26	0.08	0.15	-0.2	0.19	0.68	0.02	0.76	-0.43	0.52	-0.34	0.67	0.2	-0.64	-0.12	0.36	0.45	-0.05	-0.38	0.77	0.39	0.47	-0.26	0.18
Other Current Liab	0.88	0.26		-0.86	0.83	-0.93	0.86	0.78	-0.89	-0.38	-0.91	0.91	0.74	0.78	0.73	0.29	0.82	0.95	0.81	0.78	-0.01	0.8	0.85	0.87	-0.7	0.83
Total Current Liabilities	-0.93	0.08	-0.86		-0.8	0.88	-0.8	-0.65	1.0	0.64	0.8	-0.77	-0.86	-0.65	-0.82	-0.42	-0.92	-0.75	-0.63	-0.85	-0.27	-0.48	-0.79	-0.73	0.58	-0.78
Total Stockholder Equity	0.96	0.15	0.83	-0.8		-0.97	1.0	0.74	-0.81	-0.27	-0.86	0.86	0.5	0.7	0.42	0.57	0.94	0.62	0.73	0.97	-0.36	0.69	0.94	0.92	-0.95	1.0
Other Liab	-0.98	-0.2	-0.93	0.88	-0.97		-0.97	-0.79	0.89	0.33	0.89	-0.93	-0.62	-0.8	-0.61	-0.46	-0.94	-0.76	-0.73	-0.94	0.19	-0.75	-0.96	-0.95	0.87	-0.96
Net Tangible Assets	0.96	0.19	0.86	-0.8	1.0	-0.97		0.76	-0.82	-0.26	-0.89	0.87	0.52	0.71	0.44	0.53	0.93	0.66	0.78	0.96	-0.36	0.72	0.94	0.93	-0.95	1.0
Property Plant And Equipment Net	0.7	0.68	0.78	-0.65	0.74	-0.79	0.76		-0.7	0.12	-0.93	0.93	0.33	0.94	0.68	-0.14	0.6	0.74	0.84	0.61	-0.17	0.91	0.88	0.88	-0.67	0.74
Current Deferred Revenue	-0.93	0.02	-0.89	1.0	-0.81	0.89	-0.82	-0.7		0.61	0.85	-0.79	-0.86	-0.68	-0.83	-0.38	-0.91	-0.79	-0.7	-0.85	-0.24	-0.53	-0.81	-0.75	0.6	-0.79
Net Debt	-0.47	0.76	-0.38	0.64	-0.27	0.33	-0.26	0.12	0.61		0.18	-0.04	-0.87	0.14	-0.42	-0.61	-0.56	-0.32	-0.12	-0.43	-0.58	0.26	-0.09	-0.02	0.03	-0.24
Retained Earnings	-0.85	-0.43	-0.91	0.8	-0.86	0.89	-0.89	-0.93	0.85	0.18		-0.92	-0.58	-0.83	-0.69	-0.14	-0.78	-0.83	-0.94	-0.76	0.12	-0.84	-0.89	-0.88	0.74	-0.86
Accounts Payable	0.85	0.52	0.91	-0.77	0.86	-0.93	0.87	0.93	-0.79	-0.04	-0.92		0.45	0.96	0.68	0.12	0.76	0.82	0.77	0.77	-0.2	0.92	0.96	0.98	-0.79	0.86
Cash	0.69	-0.34	0.74	-0.86	0.5	-0.62	0.52	0.33	-0.86	-0.87	-0.58	0.45		0.3	0.75	0.4	0.71	0.73	0.51	0.58	0.54	0.2	0.43	0.38	-0.24	0.48
Non Current Assets Total	0.7	0.67	0.78	-0.65	0.7	-0.8	0.71	0.94	-0.68	0.14	-0.83	0.96	0.3		0.71	-0.13	0.58	0.74	0.66	0.6	-0.13	0.9	0.9	0.9	-0.64	0.7
Non Currrent Assets Other	0.6	0.2	0.73	-0.82	0.42	-0.61	0.44	0.68	-0.83	-0.42	-0.69	0.68	0.75	0.71		-0.15	0.53	0.8	0.54	0.43	0.58	0.5	0.58	0.53	-0.17	0.4
Other Assets	0.57	-0.64	0.29	-0.42	0.57	-0.46	0.53	-0.14	-0.38	-0.61	-0.14	0.12	0.4	-0.13	-0.15		0.68	0.03	0.06	0.68	-0.25	-0.12	0.3	0.27	-0.55	0.55
Cash And Short Term Investments	0.99	-0.12	0.82	-0.92	0.94	-0.94	0.93	0.6	-0.91	-0.56	-0.78	0.76	0.71	0.58	0.53	0.68		0.61	0.62	0.99	-0.09	0.49	0.86	0.81	-0.82	0.93
Net Receivables	0.7	0.36	0.95	-0.75	0.62	-0.76	0.66	0.74	-0.79	-0.32	-0.83	0.82	0.73	0.74	0.8	0.03	0.61		0.77	0.54	0.17	0.78	0.69	0.73	-0.46	0.61
Common Stock Shares Outstanding	0.68	0.45	0.81	-0.63	0.73	-0.73	0.78	0.84	-0.7	-0.12	-0.94	0.77	0.51	0.66	0.54	0.06	0.62	0.77		0.6	-0.17	0.78	0.72	0.73	-0.65	0.75
Short Term Investments	0.98	-0.05	0.78	-0.85	0.97	-0.94	0.96	0.61	-0.85	-0.43	-0.76	0.77	0.58	0.6	0.43	0.68	0.99	0.54	0.6		-0.24	0.52	0.89	0.84	-0.89	0.96
Non Current Liabilities Total	-0.1	-0.38	-0.01	-0.27	-0.36	0.19	-0.36	-0.17	-0.24	-0.58	0.12	-0.2	0.54	-0.13	0.58	-0.25	-0.09	0.17	-0.17	-0.24		-0.37	-0.29	-0.37	0.63	-0.4
Inventory	0.61	0.77	0.8	-0.48	0.69	-0.75	0.72	0.91	-0.53	0.26	-0.84	0.92	0.2	0.9	0.5	-0.12	0.49	0.78	0.78	0.52	-0.37		0.82	0.89	-0.7	0.7
Other Current Assets	0.92	0.39	0.85	-0.79	0.94	-0.96	0.94	0.88	-0.81	-0.09	-0.89	0.96	0.43	0.9	0.58	0.3	0.86	0.69	0.72	0.89	-0.29	0.82		0.99	-0.88	0.94
Other Stockholder Equity	0.88	0.47	0.87	-0.73	0.92	-0.95	0.93	0.88	-0.75	-0.02	-0.88	0.98	0.38	0.9	0.53	0.27	0.81	0.73	0.73	0.84	-0.37	0.89	0.99		-0.9	0.93
Total Liab	-0.84	-0.26	-0.7	0.58	-0.95	0.87	-0.95	-0.67	0.6	0.03	0.74	-0.79	-0.24	-0.64	-0.17	-0.55	-0.82	-0.46	-0.65	-0.89	0.63	-0.7	-0.88	-0.9		-0.96
Net Invested Capital	0.95	0.18	0.83	-0.78	1.0	-0.96	1.0	0.74	-0.79	-0.24	-0.86	0.86	0.48	0.7	0.4	0.55	0.93	0.61	0.75	0.96	-0.4	0.7	0.94	0.93	-0.96

Click cells to compare fundamentals

Neuropace Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

VWITX	Vanguard Intermediate Term Tax Exempt
VGSTX	Vanguard Star Fund
VFIAX	Vanguard 500 Index

When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:

How To Invest In Neuropace

Details

Is Neuropace Stock a good investment?

Details

What is Neuropace's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.

Note that the Neuropace information on this page should be used as a complementary analysis to other Neuropace's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Neuropace Stock analysis

When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.

	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	CEOs Directory Screen CEOs from public companies around the world
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Global Correlations Find global opportunities by holding instruments from different markets
	Money Managers Screen money managers from public funds and ETFs managed around the world
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Stocks Directory Find actively traded stocks across global markets
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Technical Analysis Check basic technical indicators and analysis based on most latest market data

Is Neuropace's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.27)

Revenue Per Share

2.531

Quarterly Revenue Growth

0.408

Return On Assets

(0.15)

Return On Equity

(1.19)

The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neuropace Short Term Debt vs Total Liab Analysis

Short Term Debt vs Total Liab

Short Term Debt vs Total Liab Correlation Analysis

Correlation Coefficient

Short Term Debt

Total Liab

Neuropace fundamental ratios Correlations

Neuropace Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Complementary Tools for Neuropace Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Current Deferred Revenue	+ 1.0	Total Current Liabilities
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Net Tangible Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Short Term Investments	+ 0.99	Cash And Short Term Investments

Other Liab	- 0.98	Total Assets
Net Tangible Assets	- 0.97	Other Liab
Other Liab	- 0.97	Total Stockholder Equity
Net Invested Capital	- 0.96	Total Liab
Net Invested Capital	- 0.96	Other Liab
Other Current Assets	- 0.96	Other Liab